About Malecare

This author has not yet filled in any details.
So far Malecare has created 608 blog entries.

High Volume Radiation Treatment Facilities Produce Better Survival In Men with Aggressive Prostate Cancer

According to researchers at Brigham and Women’s Hospital in Boston Ma., men with aggressive prostate cancer who have radiation therapy to treat the cancer have better overall survival rates when the therapy is given at a high volume treatment facility. Paul Nguyen, MD, a physician researcher in the department of Radiation Oncology at Brigham said, “Our paper shows that [...]

Salvage Radical Prostatectomy Improves Long Term Survival in Men with Radiation Recurrent Prostate Cancer

A retrospective study, using the SEER Date, a U.S. national database, analyzed data from men diagnosed with prostate cancer and found that salvage radical prostatectomy (SRP) improved the long-term survival in men whose cancer has returned after receiving radiation therapy. We know that approximately 30% of men who have radiation therapy as their primary therapy will have a recurrence [...]

Belfast Clinical Trial Combining Two Radio-Therapies For Men With Advanced Prostate Cancer

Researchers at Queen’s University in Belfast along with the Belfast Trust are conducting a clinical trial evaluating the combination of two radiotherapy treatments, Radium 223 and Pelvic Radiation using Volumetric Modulated Arc Therapy (VMAT) in men with bone positive advanced prostate cancer. The trial, being called ADRRAD trial, involves combining androgen deprivation therapy (ADT) along [...]

Levels of Serum Alkaline Phosphatase Reflect Negative Prostate Cancer Bone Activity

Not often discussed, but a valuable measure of prostate cancer bone activity is serum (in the blood) alkaline phosphatase. It is a normal enzyme produced naturally by the body. Everyone produces some of this enzyme regardless of his or her state of health, gender, or age. The tissues that produce the most alkaline phosphatase are the [...]

Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss as a side effect of the ADT. Using transdermal (skin patches) oestradiol is a potential alternative to [...]

Real Life Issues About Abiraterone Acetate (Zytiga) Prior to Chemotherapy – Unanticipated Real-World Clinical Experience Worth Noting

Researchers in Hong Kong wanted to confirm the efficacy of abiraterone acetate (Zytiga) used prior to chemotherapy that had been shown in the trial setting. In their analysis they came up short; raising some very significant concerns about Zytiga’s efficacy when used prior to chemotherapy. They reviewed the clinical records of men with metastatic castrate [...]

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Phase II Results

We know that prostate cancer is a heterogeneous disease, but most of our treatments are not based on the different molecular stratification exhibited by the disease. One of the differences we do recognize in the cancer is that some of the tumors have genetic DNA-repair defects. There has been evidence that in those cancers exhibiting [...]

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]

UK’s NICE Reverses Itself and Now Recommends Zytiga To Treat Men Before Chemotherapy

In a sudden reversal of its prior opinion the UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Janssen’s Zytiga (abiraterone) to treat advanced prostate cancer before chemotherapy. Its prior recommendation was not to approve Zytiga. TAccording to NICE their decision to change their December 2015 recommendation follows the submission [...]

Men With Castrate Resistant Prostate Cancer Can Experience A PSA Flare When Starting Docetaxel Chemotherapy

The PSA flare phenomenon when first starting chemotherapy with docetaxel has been noted by many clinicians. To evaluate this flare in men with castrate resistant prostate cancer treated with docetaxel, researchers retrospectively evaluated the charts of 56 men who received docetaxel-based chemotherapy in three different centers from August 1999 to August 2007. They found that [...]

Go to Top